EVIDENCE PROFILE / PUBLISHED
Epithalon
A synthetic Ala-Glu-Asp-Gly tetrapeptide, also called Epitalon, with small biomarker studies and cell/animal findings that do not establish sleep, longevity, or anti-aging benefits in people.
Evidence at a glance
- Human
- LimitedThree human studies, mostly measuring biomarkers.
- Animal/cell
- LimitedTwo cell studies and some small animal studies.
- Approved medicine
- None foundScope: the Canadian and U.S. sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“Longer telomeres in a dish are not longer life in a person. A biomarker is not a birthday counter.”
Epithalon is surrounded by longevity language. The evidence is better described as a short list of biomarker and laboratory observations, plus large unanswered questions about identity, clinical outcomes, and safety.
Identity and established aliases
Epitalon (spelled Epithalon in the catalogue and some papers) is the synthetic tetrapeptide Ala-Glu-Asp-Gly, often shortened to AEDG. FDA distinguishes it from epithalamin, a complex mixture of peptides historically extracted from cattle pineal glands. Findings for epithalamin cannot be assigned to Epitalon.
FDA separately evaluated free base and acetate and found incomplete characterization. Spelling variants do not resolve salt form, purity, or formulation.
Why researchers study it
Research questions have centred on circadian biology, melatonin-related biomarkers, gene expression, telomerase, telomere length, cellular senescence, and aging models. These are heterogeneous mechanisms and surrogate endpoints, not a single established biological role.
Approved medicines and investigational uses
No active-ingredient record was returned by Health Canada's Drug Product Database under Epitalon or Epithalon on the access date. FDA states that neither Epitalon free base nor acetate is a component of an FDA-approved drug. A U.S. orphan designation related to retinitis pigmentosa was later withdrawn; orphan designation itself was never marketing approval.
Human studies have explored circadian-gene expression and a urinary melatonin metabolite in night-shift workers, and one report described parabulbar administration in retinitis pigmentosa. FDA evaluated a nomination for insomnia but found no study in patients with insomnia and no clinically meaningful sleep outcomes.
What human studies show
FDA found three human administration studies. Two used sublingual Epitalon in night-shift workers and measured circadian-gene expression or urinary 6-sulfatoxymelatonin. In one randomized placebo-controlled study of 75 women, the treated low-melatonin subgroup showed a biomarker increase, but blinding was not specified, the study was short, subjective wellbeing measurement was unclear, and no sleep endpoint was assessed.
A retinitis-pigmentosa report used a different local ocular route and did not establish an approved medicine. The reviewed studies do not demonstrate treatment of insomnia, slower aging, longer life, dementia prevention, or broad restoration of health.
What cells and animal studies show
A 2003 study reported telomerase expression and telomere elongation in cultured human fetal fibroblasts. A 2025 cell study reported telomere-related changes in normal and cancer cell lines. FDA also reviewed small animal studies of circadian hormones, lifespan, and tumours, finding limitations in scope, duration, sex representation, dose-response, and historical controls.
Human cells in culture are a preclinical model, even when the cells came from humans. Telomerase activation can be scientifically interesting while also raising unresolved safety questions because telomere maintenance is relevant to cancer biology.
Popular claims and evidence limits
Popular claims include deeper sleep, restored melatonin, longer telomeres, reversal of aging, longer lifespan, disease prevention, immune effects, and improved skin or mood. FDA found insufficient evidence for insomnia and did not evaluate many broader nominated claims because adequate supporting information was not supplied. None of the reviewed human studies measured lifespan or demonstrated anti-aging benefit.
What remains uncertain
There is no adequate route-specific human safety database, no established clinical benefit, and no clear long-term assessment of carcinogenic, reproductive, immune, or endocrine effects. FDA highlighted possible immunogenicity, aggregation, and peptide impurities for proposed injection and a theoretical carcinogenic concern around telomerase activation; the clinical relevance is unknown, not proven.
